Monotherapy with Rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmcytic lymphoma

Leukemia and Lymphoma

Volumn 42, Issue 6, 2001, Pages 1405-1408

  Cohen, Yossi ^a   Polliack, Aaron ^a   Zelig, Orly ^a   Goldfarb, Ada ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Anti CD20 antibody; Cold agglutinin mediated hemolytic anemia; Indolent B cell lymphoma; NHL; Rapid remission; Rituximab

Indexed keywords

CHLORAMBUCIL; COLD AGGLUTININ; DEXAMETHASONE; FLUDARABINE; IMMUNOGLOBULIN M; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB;

AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; B CELL LYMPHOMA; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; FEMALE; FOLLOW UP; HEMOLYSIS; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; REFRACTORY ANEMIA;

EID: 0035691927     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109097770     Document Type: Article

References (15)

1. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of the patients respond to a four-dose treatment program
2. Extended Rituximab (anti CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
3. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti CD20 monoclonal antibody and CHOP chemotherapy
4. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma
5. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-D2B8)
6. European phase 2 study of rituximab (chimeric anti CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
7. Rituximab (anti CD20 antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase 2 study
8. Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomised GELA trial
9. Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity
10. Induction of complete haematological remission after monotherapy with anti CD20 monoclonal antibody (rituximab) in a patient with alkylating agent resistant Waldenstrom's macroglobulinemia
11. Molecular eradication of the BCL2/IgH gene after sequential therapy with CHOP and anti-CD20 (rituximab) monoclonal antibody in previously untreated follicular NHL patients
12. Rituxan in the treatment of cold agglutinin disease
13. Rituxan (rituximab) therapy for chronic cold agglutinin disease
14. Rituxan in the treatment of chronic idiopathic thrombocytopenic purpura (ITP)
15. A pilot study of anti-CD20 MoAb rituximab in patients with refractory immune thrombocytopenic purpura (ITP)